Roxadustat in the Treatment of Anemia in End Stage Renal Disease (ESRD) Patients on Stable Dialysis
Status:
Completed
Trial end date:
2018-07-06
Target enrollment:
Participant gender:
Summary
This study was conducted to explore a new therapy for anemia in participants with end stage
renal disease (ESRD) on dialysis. Anemia is a reduced number of red blood cells or
hemoglobin. Hemoglobin (which contains iron) is important for the transport of oxygen in your
blood. The purpose of this study was to evaluate if roxadustat is effective and safe in the
maintenance treatment of anemia in ESRD participants on stable dialysis. Roxadustat was
compared to epoetin alfa and darbepoetin alfa, commercially available medicines for treatment
of anemia.